Real-Life Effectiveness and Safety of Baricitinib in 17 Japanese Patients With Alopecia Areata: A 60-Week Single Center Study

    Akihiko Uchiyama, Takeshi Araki, Keiji Kosaka, Sei‐ichiro Motegi
    Studysummary In this study, the researchers reported that baricitinib improved hair loss in a real-world setting for Japanese adults with alopecia areata, with a 64.7% success rate at 60 weeks, though prolonged episodes reduced efficacy. Common side effects were acne and mildly decreased renal function.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontierspartnerships.org →
    Discuss this study in the Community →

    Research cited in this study 15

    1. Case Report: Sequential Therapy with Dupilumab and Baricitinib for Severe Alopecia Areata with Atopic Dermatitis in Children Frontiers in immunology · 2024
    2. Comparative Efficacy of Oral Janus Kinase Inhibitors and Biologics in Adult Alopecia Areata: A Systematic Review and Bayesian Network Meta-Analysis Journal of the European Academy of Dermatology and Venereology · 2024
    3. Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients Acta dermato-venereologica · 2024
    4. Baricitinib for the Treatment of Alopecia Areata in Adults: Real-World Analysis of 36 Patients Journal of the American Academy of Dermatology · 2024
    5. Effectiveness and Safety of Baricitinib in Patients With Moderate-to-Severe Refractory Alopecia Areata in Real World: An Open-Label, Single-Center Study Journal of Cosmetic Dermatology · 2023
    6. Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials British Journal of Dermatology · 2023
    7. Switching Between Tofacitinib and Baricitinib in Alopecia Areata: A Review of Clinical Response Journal of the American Academy of Dermatology · 2023
    8. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    9. Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway Indian Dermatology Online Journal · 2023
    10. Prevalence of Alopecia Areata in Japan: Estimates from a Nationally Representative Sample The Journal of Dermatology · 2022
    11. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    12. Prevalence and Risk Factors Associated with the Occurrence of Autoimmune Diseases in Patients with Alopecia Areata Journal of Inflammation Research · 2021
    13. Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata JCI insight · 2021
    14. Development of Clinician-Reported Outcome and Patient-Reported Outcome Measures for Eyebrow, Eyelash, and Nail Assessment in Alopecia Areata American Journal of Clinical Dermatology · 2020
    15. The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials British Journal of Dermatology · 2020

    Related research 1

    1. Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child International journal of research in dermatology · 2019